About Medex Capital


Portfolio Management and Research


Bartjan van Hulten

Portfolio Management and Research

Prior to founding Medex in 2011, Bartjan was at Fidelity Investments where he became healthcare team leader, managing and advising a broad range of global healthcare investments in excess of $5bn across a number of portfolios, with a track record of alpha generation in both up and down markets. Prior to that, from 1998 to 2003, he led the healthcare research team at MeesPierson (ABNAmro), covering European and US healthcare companies. He has a MSc in Physics from Delft University of Technology, a MBA from Insead, and is a CFA charter holder.


Roland Maier

Research

Prior to joining Medex, Roland worked at Bellevue Asset Management as a Portfolio Manager of BB Biotech, a $1-2bn healthcare investment company, with a track record of outperformance since he took on the role in 2003 Prior to BB Biotech, he was at BASF Pharma, with focus on development and prioritization of the company's therapeutic areas and clinical development projects. He obtained a MSc in Biochemistry from the Federal Institute of Technology Zurich, and a MBA from University of St. Gallen.


Operational Support, Risk Oversight and Compliance


Privium Fund Management (UK) Ltd

Investment Manager

Privium is an independent investment management solutions firm which provides support to investment advisors such as Medex, so that we can dedicate all our focus on our core activity: investing and generating attractive returns for clients. Through dedicated staff, Privium brings together operational support, compliance monitoring, reporting, and independent risk oversight. As an industry expert, Privium brings the know-how to efficiently connect the various service providers and to provide a robust institutional infrastructure that nowadays is essential in the investment industry.

Privium has offices in London, Amsterdam, and Hong Kong. In the UK, Privium is authorised and regulated by the FCA under license number 471186.